Big 3 PBM formularies favor private-label biosimilars

The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars – RetailWit

For 2025, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)—have again each excluded hundreds of drugs from their standard formularies. You can find our updated counting below. As you’ll see below, the combination of formulary exclusion and private labels is creating an increasingly confusing and crowded biosimilar marketplace. For 2025, the Big Three PBMs shifte…

Big 3 PBM formularies favor private-label biosimilars

In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.

A Banner Year for Biosimilars: The 19 FDA Approvals From 2024

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.

Biosimilars in the UK: Insights from Biocon Biologics

Biocon Biologics talks about biosimilar trends, industry collaboration, and business development